Ari M Melnick

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6259331/publications.pdf

Version: 2024-02-01

424	39,564	2203	3312
papers	citations	99 h-index	184 g-index

428	428	428	47512
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2022, 63, 789-798.	0.6	12
2	Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. Blood Cancer Discovery, 2022, 3, 50-65.	2.6	14
3	Landscape and clinical significance of long noncoding <scp>RNAs</scp> involved in multiple myeloma expressed fusion transcripts. American Journal of Hematology, 2022, 97, .	2.0	1
4	Intravital three-photon microscopy allows visualization over the entire depth of mouse lymph nodes. Nature Immunology, 2022, 23, 330-340.	7.0	26
5	System-wide transcriptome damage and tissue identity loss in COVID-19 patients. Cell Reports Medicine, 2022, 3, 100522.	3.3	24
6	Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms. Frontiers in Cell and Developmental Biology, 2022, 10, 814216.	1.8	2
7	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine, 2022, 14, eabb7695.	5.8	13
8	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	3.9	12
9	Loss of function mutations of BCOR in classical Hodgkin lymphoma. Leukemia and Lymphoma, 2022, 63, 1080-1090.	0.6	2
10	SETD2 Haploinsufficiency Enhances Germinal Centerâ€“Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer Discovery, 2022, 12, 1782-1803.	7.7	14
11	Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants. Biophysical Journal, 2022, 121, 3753-3764.	0.2	5
12	3D chromosomal architecture in germinal center B cells and its alterations in lymphomagenesis. Current Opinion in Genetics and Development, 2022, 74, 101915.	1.5	2
13	Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. Nature Biotechnology, 2022, 40, 1488-1499.	9.4	46
14	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	0.6	512
15	Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood Reviews, 2022, 56, 100988.	2.8	6
16	Diverging regulation of Bach2 protein and RNA expression determine cell fate in early B cell response. Cell Reports, 2022, 40, 111035.	2.9	4
17	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood, 2021, 137, 788-800.	0.6	22
18	The Role of Epigenetic Mechanisms in B Cell Lymphoma Pathogenesis. Annual Review of Cancer Biology, 2021, 5, 311-330.	2.3	3

#	Article	IF	Citations
19	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature, 2021, 589, 299-305.	13.7	155
20	H1 histones control the epigenetic landscape by local chromatin compaction. Nature, 2021, 589, 293-298.	13.7	101
21	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood, 2021, 137, 812-825.	0.6	18
22	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. Leukemia, 2021, 35, 2688-2692.	3.3	7
23	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell, 2021, 39, 240-256.e11.	7.7	143
24	Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Leukemia, 2021, 35, 1438-1450.	3.3	28
25	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discovery, 2021, 11, 1468-1489.	7.7	119
26	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood, 2021, 138, 370-381.	0.6	33
27	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nature Communications, 2021, 12, 1660.	5.8	132
28	An Esrrb and Nanog Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions. Frontiers in Cell and Developmental Biology, 2021, 9, 630067.	1.8	8
29	Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond. Journal of Medicinal Chemistry, 2021, 64, 4333-4358.	2.9	16
30	Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. Blood Cancer Discovery, 2021, 2, 198-200.	2.6	3
31	Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML. Blood, 2021, 138, 160-177.	0.6	13
32	Molecular classification improves risk assessment in adult BCR-ABL1â€“negative B-ALL. Blood, 2021, 138, 948-958.	0.6	59
33	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). Current Cancer Drug Targets, 2021, 21, 274-282.	0.8	10
34	Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. Leukemia, 2021, 35, 3012-3016.	3.3	11
35	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. IScience, 2021, 24, 102651.	1.9	4
36	Abstract LB014: Translational activation of ATF4 through mitochondrial anaplerotic metabolic pathways is required for DLBCL growth and survival. , 2021, , .		0

#	Article	IF	Citations
37	OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. Nature Immunology, 2021, 22, 1327-1340.	7.0	11
38	Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. Frontiers in Immunology, 2021, 12, 688493.	2.2	5
39	Dissecting bulk transcriptomes of diffuse large B cell lymphoma. Cancer Cell, 2021, 39, 1305-1307.	7.7	2
40	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. Nature Communications, 2021, 12, 5406.	5.8	29
41	Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer. Cancer Research, 2021, 81, 6061-6070.	0.4	11
42	Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discovery, 2021, 11, 1542-1561.	7.7	133
43	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nature Immunology, 2021, 22, 240-253.	7.0	24
44	Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. Journal of Experimental Medicine, 2021, 218, .	4.2	29
45	An Autochthonous Mouse Model ofMyd88- andBCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood Cancer Discovery, 2021, 2, 70-91.	2.6	21
46	MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 269-269.	0.6	2
47	Evolution of the Tumor Microenvironment throughout Progression and Transformation of EZH2 Mutant Follicular Lymphoma. Blood, 2021, 138, 446-446.	0.6	1
48	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. Blood, 2021, 138, 413-413.	0.6	1
49	BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells. Blood, 2021, 138, 359-359.	0.6	2
50	Complex Structural Variation Associated with Enhancer Hijacking and Loss of Tumor Suppressors in Mantle Cell Lymphoma. Blood, 2021, 138, 675-675.	0.6	0
51	Sirtuin 3 Inhibition Targets AML Stem Cells through Perturbation of Fatty Acid Oxidation. Blood, 2021, 138, 2240-2240.	0.6	1
52	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Frontiers in Cell and Developmental Biology, 2021, 9, 805195.	1.8	7
53	The SEQC2 epigenomics quality control (EpiQC) study. Genome Biology, 2021, 22, 332.	3.8	20
54	The therapeutic landscape for cells engineered with chimeric antigen receptors. Nature Biotechnology, 2020, 38, 233-244.	9.4	147

#	Article	IF	Citations
55	Clonal Hematopoiesis Before, During, and After Human Spaceflight. Cell Reports, 2020, 33, 108458.	2.9	30
56	Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. Molecular Cell, 2020, 80, 845-861.e10.	4.5	21
57	Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. Cell Reports, 2020, 33, 108448.	2.9	35
58	Multi-omic, Single-Cell, and Biochemical Profiles of Astronauts Guide Pharmacological Strategies for Returning to Gravity. Cell Reports, 2020, 33, 108429.	2.9	37
59	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. IScience, 2020, 23, 101844.	1.9	31
60	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Advances, 2020, 4, 5226-5231.	2.5	28
61	The dangers of dÃ©jÃ vu: memory B cells as the cells of origin of ABC-DLBCLs. Blood, 2020, 136, 2263-2274.	0.6	25
62	Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML. Cancer Discovery, 2020, 10, 1934-1949.	7.7	23
63	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research, 2020, 30, 1217-1227.	2.4	35
64	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell, 2020, 37, 655-673.e11.	7.7	93
65	TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. Science Advances, 2020, 6, eaay5872.	4.7	29
66	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. Nature Cancer, 2020, 1, 653-664.	5.7	35
67	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell, 2020, 182, 297-316.e27.	13.5	63
68	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discovery, 2020, 10, 440-459.	7.7	103
69	Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a034959.	2.9	14
70	The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. PLoS ONE, 2020, 15, e0231470.	1.1	10
71	BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL. Blood, 2020, 136, 2-3.	0.6	4
72	Targeted detection and quantitation of histone modifications from 1,000 cells. PLoS ONE, 2020, 15, e0240829.	1.1	3

#	Article	IF	Citations
73	The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 34-34.	0.6	1
74	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
75	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
76	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
77	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
78	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
79	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
80	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
81	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
82	ExÂvivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells. Biomaterials, 2019, 198, 27-36.	5.7	39
83	Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. Genes and Development, 2019, 33, 1265-1279.	2.7	17
84	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell, 2019, 36, 194-209.e9.	7.7	184
85	MTA2/NuRD Regulates B Cell Development and Cooperates with OCA-B in Controlling the Pre-B to Immature B Cell Transition. Cell Reports, 2019, 28, 472-485.e5.	2.9	28
86	Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer Cell, 2019, 36, 402-417.e13.	7.7	69
87	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discovery, 2019, 9, 546-563.	7.7	213
88	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell, 2019, 35, 916-931.e9.	7.7	70
89	BCL6 modulates tissue neutrophil survival and exacerbates pulmonary inflammation following influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11888-11893.	3.3	58
90	Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1694-1698.	1.0	14

#	Article	IF	Citations
91	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer Discovery, 2019, 9, 872-889.	7.7	36
92	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature Communications, 2019, 10, 1874.	5.8	63
93	The Impact of Heterogeneity on Single-Cell Sequencing. Frontiers in Genetics, 2019, 10, 8.	1.1	84
94	Emerging epigenetic-modulating therapies in lymphoma. Nature Reviews Clinical Oncology, 2019, 16, 494-507.	12.5	80
95	Germinal centerâ€derived lymphomas: The darkest side of humoral immunity. Immunological Reviews, 2019, 288, 214-239.	2.8	113
96	The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. Science, 2019, 364, .	6.0	576
97	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood, 2019, 133, 2401-2412.	0.6	54
98	Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1336-1339.	1.0	15
99	Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nature Communications, 2019, 10, 821.	5.8	73
100	BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. Cancer Discovery, 2019, 9, 662-679.	7.7	31
101	An â€œEZâ€•Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?. Cancer Discovery, 2019, 9, 1158-1160.	7.7	4
102	Role of chromosomal architecture in germinal center B cells and lymphomagenesis. Current Opinion in Hematology, 2019, 26, 294-302.	1.2	7
103	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature Immunology, 2019, 20, 86-96.	7.0	71
104	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	0.6	21
105	Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome. Blood, 2019, 134, 23-23.	0.6	6
106	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. Blood, 2019, 134, 393-393.	0.6	0
107	Characterization of Complete Lncrnas Transcriptome Reveals Expression of Lncrnas As a Prognostic Factor and Linc-Smilo As a Potential Therapeutic Target in Multiple Myeloma. Blood, 2019, 134, 4323-4323.	0.6	1
108	Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. Blood, 2019, 134, 173-173.	0.6	0

#	Article	IF	Citations
109	Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas. Blood, 2019, 134, 2073-2073.	0.6	3
110	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. Blood, 2019, 134, 1239-1239.	0.6	0
111	EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche. Blood, 2019, 134, 2768-2768.	0.6	3
112	ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer Cell, 2018, 33, 495-511.e12.	7.7	216
113	How Biophysical Forces Regulate Human B Cell Lymphomas. Cell Reports, 2018, 23, 499-511.	2.9	30
114	MEF2C Phosphorylation Is Required forÂChemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2018, 8, 478-497.	7.7	59
115	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nature Communications, 2018, 9, 222.	5.8	51
116	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell, 2018, 33, 44-59.e8.	7.7	71
117	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discovery, 2018, 8, 1632-1653.	7.7	120
118	Untangling the Role of Polycomb Complexes in Chemotherapy Resistance. Cancer Discovery, 2018, 8, 1348-1351.	7.7	3
119	Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. Journal of Medicinal Chemistry, 2018, 61, 7573-7588.	2.9	35
120	Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood, 2018, 132, 1265-1278.	0.6	39
121	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood, 2018, 132, 2026-2039.	0.6	48
122	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. Journal of Clinical Investigation, 2018, 128, 4397-4412.	3.9	51
123	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. Blood, 2018, 132, 2854-2854.	0.6	0
124	Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. Cancer Research, 2017, 77, 1818-1830.	0.4	13
125	Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. Blood, 2017, 129, 1779-1790.	0.6	18
126	DNA Methylationâ€“Based Biomarkers. Journal of Clinical Oncology, 2017, 35, 793-795.	0.8	7

#	Article	IF	Citations
127	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery, 2017, 7, 506-521.	7.7	43
128	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discovery, 2017, 7, 494-505.	7.7	94
129	Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discovery, 2017, 7, 868-883.	7.7	101
130	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics, 2017, 49, 866-875.	9.4	75
131	Follicular lymphoma: Stateâ€ofâ€theâ€art ICML workshop in Lugano 2015. Hematological Oncology, 2017, 35, 397-407.	0.8	11
132	Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation. ACS Biomaterials Science and Engineering, 2017, 3, 214-225.	2.6	28
133	Untangling the Web of Lymphoma Somatic Mutations. Cell, 2017, 171, 270-272.	13.5	1
134	MALT1 Inhibition Is Efficacious in Both NaÃ¯ve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. Cancer Research, 2017, 77, 7038-7048.	0.4	41
135	EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nature Communications, 2017, 8, 877.	5.8	132
136	The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nature Medicine, 2017, 23, 1369-1376.	15.2	971
137	Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Science Translational Medicine, 2017, 9, .	5.8	52
138	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	7.7	218
139	The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clinical Cancer Research, 2017, 23, 885-893.	3.2	133
140	Central role of myeloid MCPIP1 in protecting against LPS-induced inflammation and lung injury. Signal Transduction and Targeted Therapy, 2017, 2, 17066.	7.1	48
141	SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls. Blood, 2017, 130, 643-643.	0.6	9
142	m6a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia. Blood, 2017, 130, 791-791.	0.6	0
143	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. Blood, 2017, 130, 645-645.	0.6	0
144	General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute, 2016, 108, djw250.	3.0	2

#	Article	IF	Citations
145	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications, 2016, 7, 11889.	5.8	42
146	DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discovery, 2016, 6, 501-515.	7.7	73
147	The many layers of epigenetic dysfunction in B-cell lymphomas. Current Opinion in Hematology, 2016, 23, 377-384.	1.2	35
148	Genetic and epigenetic heterogeneity in acute myeloid leukemia. Current Opinion in Genetics and Development, 2016, 36, 100-106.	1.5	130
149	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood, 2016, 127, 858-868.	0.6	76
150	miR-181a negatively regulates NF-ÎºB signaling and affects activated B-cellâ€“like diffuse large B-cell lymphoma pathogenesis. Blood, 2016, 127, 2856-2866.	0.6	37
151	The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature, 2016, 538, 397-401.	13.7	233
152	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell, 2016, 30, 197-213.	7.7	200
153	SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. Cancer Research, 2016, 76, 5467-5478.	0.4	55
154	A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. Molecular Cell, 2016, 63, 711-719.	4.5	128
155	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science Translational Medicine, 2016, 8, 366ra161.	5.8	144
156	Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity, 2016, 45, 497-512.	6.6	112
157	Pathogenic role of B-cell receptor signaling and canonical NF-ÎºB activation in mantle cell lymphoma. Blood, 2016, 128, 82-92.	0.6	141
158	Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics, 2016, 8, 945-957.	1.0	21
159	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	15.2	195
160	Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12697-12702.	3.3	77
161	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	15.2	7
162	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 2016, 22, 792-799.	15.2	322

#	Article	IF	Citations
163	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine, 2016, 22, 379-387.	15.2	94
164	A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight, 2016, 1, .	2.3	19
165	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 3351-3362.	3.9	133
166	AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis. Blood, 2016, 128, 1045-1045.	0.6	1
167	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age â‰¥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. Blood, 2016, 128, 339-339.	0.6	7
168	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. Blood, 2016, 128, 4088-4088.	0.6	2
169	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget, 2016, 7, 3520-3532.	0.8	26
170	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	0.6	0
171	Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia. Blood, 2016, 128, 599-599.	0.6	0
172	Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML. Blood, 2016, 128, 2877-2877.	0.6	0
173	RNA Interference Screen Implicates TNFAIP3 and FOXO1 in MALT1 Inhibition Resistance. Blood, 2016, 128, 837-837.	0.6	0
174	Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia. Blood, 2016, 128, 1048-1048.	0.6	0
175	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia. Blood, 2016, 128, 907-907.	0.6	0
176	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. Blood, 2016, 128, 438-438.	0.6	0
177	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. Blood, 2016, 128, 739-739.	0.6	0
178	EZH2 Enables the Proliferation of Germinal Center B Cells and DLBCL through a Rb-E2F1 Positive Feedback Loop Involving Repression of CDKN1A. Blood, 2016, 128, 734-734.	0.6	1
179	A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports, 2015, 13, 2159-2173.	2.9	51
180	VII. Are lymphomas driven by epigenetic lesions?. Hematological Oncology, 2015, 33, 42-45.	0.8	0

#	Article	IF	Citations
181	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood, 2015, 125, 13-21.	0.6	168
182	A roadmap for discovery and translation in lymphoma. Blood, 2015, 125, 2175-2177.	0.6	18
183	Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution. Journal of Visualized Experiments, 2015, , e52246.	0.2	89
184	VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. Journal of Visualized Experiments, 2015, , e53215.	0.2	7
185	Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. Molecular Cell, 2015, 59, 89-103.	4.5	76
186	Mechanisms of action of BCL6 during germinal center B cell development. Science China Life Sciences, 2015, 58, 1226-1232.	2.3	35
187	The Epigenetic Basis of Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2015, 52, 86-96.	1.8	47
188	Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Research, 2015, 25, 478-487.	2.4	118
189	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 27, 409-425.	7.7	109
190	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 114-128.	7.7	107
191	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature, 2015, 521, 357-361.	13.7	127
192	BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. Journal of Experimental Medicine, 2015, 212, 539-553.	4.2	218
193	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6471.	5.8	41
194	Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 502-515.	7.7	191
195	Epigenomic evolution in diffuse large B-cell lymphomas. Nature Communications, 2015, 6, 6921.	5.8	111
196	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	15.2	297
197	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Experimental Medicine, 2015, 212, 1819-1832.	4.2	137
198	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports, 2015, 12, 2086-2098.	2.9	87

#	Article	IF	Citations
199	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nature Medicine, 2015, 21, 1199-1208.	15.2	359
200	Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials, 2015, 73, 110-119.	5.7	66
201	Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. Genome Medicine, 2015, 7, 110.	3.6	62
202	Musashi2 sustains the mixed-lineage leukemiaâ€“driven stem cell regulatory program. Journal of Clinical Investigation, 2015, 125, 1286-1298.	3.9	89
203	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. Journal of Clinical Investigation, 2015, 125, 4559-4571.	3.9	37
204	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1434-1434.	0.6	6
205	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age â‰¥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood, 2015, 126, 217-217.	0.6	28
206	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. Blood, 2015, 126, 306-306.	0.6	2
207	Transcriptome Sequencing Reveals Thousands of Novel Long Non-Coding RNAs in B-Cell Lymphoma. Blood, 2015, 126, 2427-2427.	0.6	0
208	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. Blood, 2015, 126, 434-434.	0.6	0
209	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. Blood, 2015, 126, 435-435.	0.6	1
210	Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. Blood, 2015, 126, 1422-1422.	0.6	0
211	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3716-3716.	0.6	0
212	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. Blood, 2015, 126, 556-556.	0.6	0
213	Histone deacetylase inhibitor treatment induces â€˜BRCAnessâ€™ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget, 2014, 5, 5637-5650.	0.8	131
214	The BCL6 RD2 Domain Governs Commitment of Activated B Cells to Form Germinal Centers. Cell Reports, 2014, 8, 1497-1508.	2.9	67
215	Dynamic evolution of clonal epialleles revealed by methclone. Genome Biology, 2014, 15, 472.	3.8	67
216	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	2.9	237

#	Article	IF	Citations
217	CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer. Cell Reports, 2014, 7, 1020-1029.	2.9	154
218	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia. Cancer Research, 2014, 74, 2520-2532.	0.4	207
219	Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends in Molecular Medicine, 2014, 20, 343-352.	3.5	148
220	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. Cellular and Molecular Bioengineering, 2014, 7, 394-408.	1.0	37
221	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology, 2014, 32, 1242-1248.	0.8	227
222	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2219-28.	3.3	78
223	Hematopoietic Stem Cell Origin of BRAF V600E Mutations in Hairy Cell Leukemia. Science Translational Medicine, 2014, 6, 238ra71.	5.8	102
224	Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer. ACS Chemical Biology, 2014, 9, 1698-1705.	1.6	23
225	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications, 2014, 5, 3904.	5.8	73
226	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood, 2014, 123, 1699-1708.	0.6	83
227	Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood, 2014, 123, 3327-3335.	0.6	52
228	Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. Blood, 2014, 123, 1012-1020.	0.6	89
229	HSC commitmentâ€“associated epigenetic signature is prognostic in acute myeloid leukemia. Journal of Clinical Investigation, 2014, 124, 1158-1167.	3.9	38
230	BCL6 Orchestrates Tfh Differentiation Via Multiple Distinct Mechanisms. Blood, 2014, 124, 4137-4137.	0.6	1
231	AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. Blood, 2014, 124, 437-437.	0.6	22
232	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. Blood, 2014, 124, 535-535.	0.6	2
233	BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain. Blood, 2014, 124, 567-567.	0.6	3
234	IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 788-788.	0.6	1

#	Article	IF	Citations
235	A Virtual B Cell Lymphoma Model to Predict Effective Combination Therapy. Blood, 2014, 124, 928-928.	0.6	2
236	Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 787-787.	0.6	0
237	PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells. Blood, 2014, 124, 262-262.	0.6	0
238	Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells. Blood, 2014, 124, 1764-1764.	0.6	1
239	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3570-3570.	0.6	0
240	Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion. Blood, 2014, 124, 364-364.	0.6	0
241	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. Blood, 2014, 124, 2963-2963.	0.6	0
242	BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia. Blood, 2014, 124, 513-513.	0.6	0
243	Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 792-792.	0.6	0
244	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 284-284.	0.6	0
245	Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program. Blood, 2014, 124, 836-836.	0.6	0
246	DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Blood, 2014, 124, 365-365.	0.6	0
247	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. Blood, 2014, 124, 69-69.	0.6	0
248	Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression. Blood, 2014, 124, 3565-3565.	0.6	0
249	Whole-Genome Epigenomic Analysis in Multiple Myeloma Reveals DNA Hypermethylation of B-Cell Specific Enhancers. Blood, 2014, 124, 2032-2032.	0.6	0
250	A stable transcription factor complex nucleated by oligomeric AML1â€“ETO controls leukaemogenesis. Nature, 2013, 500, 93-97.	13.7	134
251	New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Current Opinion in Immunology, 2013, 25, 339-346.	2.4	57
252	A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters. Cell Reports, 2013, 4, 578-588.	2.9	161

#	Article	IF	Citations
253	Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Critical Reviews in Oncology/Hematology, 2013, 88, 231-245.	2.0	26
254	DNMT1-interacting RNAs block gene-specific DNA methylation. Nature, 2013, 503, 371-376.	13.7	446
255	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood, 2013, 121, 148-155.	0.6	61
256	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine, 2013, 19, 1014-1022.	15.2	100
257	DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. Genome Research, 2013, 23, 2030-2041.	2.4	93
258	<scp>LITAF</scp>, a <scp>BCL</scp>6 target gene, regulates autophagy in mature Bâ€cell lymphomas. British Journal of Haematology, 2013, 162, 621-630.	1.2	39
259	Negative regulation of osteoclast precursor differentiation by CD11b and Î²2 integrin-B-cell lymphoma 6 signaling. Journal of Bone and Mineral Research, 2013, 28, 135-149.	3.1	52
260	PRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex. Cell Reports, 2013, 5, 1625-1638.	2.9	77
261	Structural Architecture of the CARMA1/Bcl10/MALT1 Signalosome: Nucleation-Induced Filamentous Assembly. Molecular Cell, 2013, 51, 766-779.	4.5	163
262	Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nature Immunology, 2013, 14, 380-388.	7.0	111
263	Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nature Immunology, 2013, 14, 437-445.	7.0	92
264	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	7.7	706
265	Discovering What Makes STAT Signaling TYK in T-ALL. Cancer Discovery, 2013, 3, 494-496.	7.7	3
266	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. Cancer Discovery, 2013, 3, 1002-1019.	7.7	180
267	Differentiation therapy for IDH1/2 mutant malignancies. Cell Research, 2013, 23, 975-977.	5.7	8
268	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. PLoS Genetics, 2013, 9, e1003137.	1.5	102
269	Notch activation inhibits AML growth and survival: a potential therapeutic approach. Journal of Experimental Medicine, 2013, 210, 321-337.	4.2	139
270	Induction of sarcomas by mutant IDH2. Genes and Development, 2013, 27, 1986-1998.	2.7	135

#	Article	IF	Citations
271	Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms. Cancer Research, 2013, 73, 1076-1085.	0.4	50
272	Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma. Clinical Cancer Research, 2013, 19, 6662-6668.	3.2	23
273	Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?. Expert Review of Hematology, 2013, 6, 343-345.	1.0	17
274	Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression. Cancer Research, 2013, 73, 1232-1244.	0.4	150
275	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood, 2013, 121, 5192-5202.	0.6	75
276	Downregulation of FOXP1 is required during germinal center B-cell function. Blood, 2013, 121, 4311-4320.	0.6	62
277	BCL6 breaks occur at different AID sequence motifs in Igâ€“BCL6 and non-Igâ€“BCL6 rearrangements. Blood, 2013, 121, 4551-4554.	0.6	32
278	Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2013, 123, 3099-3111.	3.9	115
279	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. Blood, 2013, 122, 1-1.	0.6	23
280	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. Blood, 2013, 122, 3736-3736.	0.6	1
281	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. Blood, 2013, 122, 634-634.	0.6	2
282	Deep Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated With Relapse In B Cell Lymphomas. Blood, 2013, 122, 79-79.	0.6	1
283	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. Blood, 2013, 122, 3760-3760.	0.6	0
284	Dynamic Changes Of DNA Methylation and a Functional Role For TET2 DNA Dioxygenase In Human Erythroid Differentiation. Blood, 2013, 122, 3415-3415.	0.6	21
285	The Bcl6 RD2 Domain Is Essential For Pre-Germinal Center B Cell Development. Blood, 2013, 122, 783-783.	0.6	0
286	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. Blood, 2013, 122, 229-229.	0.6	0
287	Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia. Blood, 2013, 122, 2499-2499.	0.6	1
288	The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells. Blood, 2013, 122, 781-781.	0.6	6

#	Article	IF	Citations
289	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. Blood, 2013, 122, 72-72.	0.6	0
290	Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia. PLoS Genetics, 2012, 8, e1002781.	1.5	263
291	Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. Cancer Discovery, 2012, 2, 1004-1023.	7.7	80
292	Oncogene-mediated alterations in chromatin conformation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9083-9088.	3.3	142
293	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood, 2012, 119, 5478-5491.	0.6	39
294	Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2. Cancer Cell, 2012, 22, 569-570.	7.7	23
295	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 2012, 44, 1179-1181.	9.4	692
296	ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. Cancer Cell, 2012, 22, 180-193.	7.7	504
297	A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells. Cell, 2012, 151, 1617-1632.	13.5	762
298	methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biology, 2012, 13, R87.	13.9	1,541
299	H2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia. Cancer Cell, 2012, 22, 194-208.	7.7	39
300	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL InÂVitro and InÂVivo. Cancer Cell, 2012, 22, 812-824.	7.7	229
301	The Bcl6-SMRT/NCoR Cistrome Represses Inflammation to Attenuate Atherosclerosis. Cell Metabolism, 2012, 15, 554-562.	7.2	111
302	Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2012, 51, 1125-1132.	1.5	29
303	IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature, 2012, 488, 656-659.	13.7	474
304	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1079-1089.	13.9	1,688
305	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	13.7	1,693
306	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood, 2012, 119, 5824-5831.	0.6	221

#	Article	IF	Citations
307	C/EBPÎ³ deregulation results in differentiation arrest in acute myeloid leukemia. Journal of Clinical Investigation, 2012, 122, 4490-4504.	3.9	50
308	Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma. PLoS ONE, 2012, 7, e40332.	1.1	44
309	Targeting Lymphomas Through MALT1 Inhibition. Oncotarget, 2012, 3, 1493-1494.	0.8	4
310	MiR-181a Is a Master Regulator of the Nuclear Factor-ÎºB Signaling Pathway in Diffuse Large B Cell Lymphoma. Blood, 2012, 120, 417-417.	0.6	0
311	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. Blood, 2012, 120, 1300-1300.	0.6	0
312	H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia. Blood, 2012, 120, 651-651.	0.6	0
313	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. Blood, 2012, 120, 776-776.	0.6	0
314	Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. Blood, 2012, 120, 1352-1352.	0.6	1
315	Next Gen Dissection of Gfi1 Dependent Transcriptome in Myeloid Progenitors Reveals Global Control of Multiple Transcriptional Programs Including Coding and Non Coding RNAs. Blood, 2012, 120, 111-111.	0.6	0
316	Enhancer Profiling Reveals SOX9 As a Novel Transcription Regulator of B Cell Activation and DLBCL Transformation. Blood, 2012, 120, 527-527.	0.6	0
317	Lineage, Fusion Partner and Age Differences in the Methylome of MLL-r Leukemias. Blood, 2012, 120, 3506-3506.	0.6	0
318	Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 64-64.	0.6	1
319	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood, 2011, 118, 3559-3569.	0.6	123
320	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. Cell, 2011, 147, 554-564.	13.5	151
321	Epigenetics and B-cell lymphoma. Current Opinion in Hematology, 2011, 18, 293-299.	1.2	60
322	Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood, 2011, 117, 234-241.	0.6	94
323	SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood, 2011, 118, 6342-6352.	0.6	93
324	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCRâ€“ABL1 kinase inhibition. Nature, 2011, 473, 384-388.	13.7	174

#	Article	IF	Citations
325	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell, 2011, 20, 11-24.	7.7	1,105
326	The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation. Science, 2011, 333, 765-769.	6.0	200
327	Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q. Journal of Biological Chemistry, 2011, 286, 25211-25223.	1.6	41
328	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. Journal of Experimental Medicine, 2011, 208, 2163-2174.	4.2	154
329	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology, 2011, 7, 818-826.	3.9	240
330	LITAF, a BCL6 Target Gene, Regulates Autophagia in B Cells and Is Essential for T-Cell Dependent Humoral Responses. Blood, 2011, 118, 1391-1391.	0.6	1
331	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. Blood, 2011, 118, 1479-1479.	0.6	1
332	ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. Blood, 2011, 118, 405-405.	0.6	4
333	Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis. PLoS Genetics, 2011, 7, e1001356.	1.5	112
334	Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas. PLoS ONE, 2011, 6, e18436.	1.1	45
335	BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. Blood, 2011, 118, 446-446.	0.6	4
336	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. Blood, 2011, 118, 1617-1617.	0.6	0
337	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. Blood, 2011, 118, 1406-1406.	0.6	0
338	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. Blood, 2011, 118, 438-438.	0.6	0
339	Development of Acute Megakaryoblastic Leukemia in Down Syndrome Is Associated with Sequential Epigenetic Changes That Target the Down Syndrome Critical Region on Chromosome 21,. Blood, 2011, 118, 3451-3451.	0.6	1
340	Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes,. Blood, 2011, 118, 3725-3725.	0.6	11
341	Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. Blood, 2011, 118, 87-87.	0.6	1
342	A Role for BCL6 in the Higher-Order Organization of Genes in DLBCL. Blood, 2011, 118, 558-558.	0.6	0

#	Article	IF	Citations
343	Conserved Transcriptional Deregulation Underlies GFI1 and ELANE Mutant Neutropenia. Blood, 2011, 118, 13-13.	0.6	1
344	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. Blood, 2011, 118, 562-562.	0.6	0
345	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. Blood, 2011, 118, 556-556.	0.6	0
346	Genomewide Detection of Genes Targeted by Aberrant Somatic Hypermutation in Lymphoma,. Blood, 2011, 118, 3474-3474.	0.6	0
347	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. Blood, 2011, 118, 585-585.	0.6	0
348	Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood, 2010, 115, 4798-4809.	0.6	108
349	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood, 2010, 116, 1025-1034.	0.6	138
350	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood, 2010, 116, 5247-5255.	0.6	262
351	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood, 2010, 116, e81-e89.	0.6	138
352	DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. Cancer Cell, 2010, 17, 13-27.	7.7	737
353	A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. Cancer Cell, 2010, 17, 400-411.	7.7	263
354	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	7.7	2,328
355	Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature Biotechnology, 2010, 28, 848-855.	9.4	1,080
356	SAFB1 Mediates Repression of Immune Regulators and Apoptotic Genes in Breast Cancer Cells. Journal of Biological Chemistry, 2010, 285, 3608-3616.	1.6	30
357	DNMT3B7, a Truncated DNMT3B Isoform Expressed in Human Tumors, Disrupts Embryonic Development and Accelerates Lymphomagenesis. Cancer Research, 2010, 70, 5840-5850.	0.4	56
358	BCL6 is critical for the development of a diverse primary B cell repertoire. Journal of Experimental Medicine, 2010, 207, 1209-1221.	4.2	108
359	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. Clinical Cancer Research, 2010, 16, 2435-2442.	3.2	25
360	Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13360-13365.	3.3	92

#	Article	IF	Citations
361	Epigenetics in AML. Best Practice and Research in Clinical Haematology, 2010, 23, 463-468.	0.7	28
362	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. Biology of Blood and Marrow Transplantation, 2010, 16, 709-728.	2.0	34
363	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. Journal of Clinical Investigation, 2010, 120, 4569-4582.	3.9	101
364	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. Blood, 2010, 116, 202-202.	0.6	1
365	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. Blood, 2010, 116, 851-851.	0.6	4
366	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. Blood, 2010, 116, 705-705.	0.6	0
367	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8368-8373.	3.3	286
368	Inhibition of DNA Methyltransferase Activates Tumor Necrosis Factor Î±â€“Induced Monocytic Differentiation in Acute Myeloid Leukemia Cells. Cancer Research, 2009, 69, 55-64.	0.4	28
369	High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Research, 2009, 37, 3829-3839.	6.5	141
370	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6â€“dependent B cell lymphomas. Nature Medicine, 2009, 15, 1369-1376.	15.2	149
371	Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 1209-1213.	0.8	322
372	Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood, 2009, 113, 2795-2804.	0.6	83
373	A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood, 2009, 113, 3397-3405.	0.6	154
374	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood, 2009, 113, 5536-5548.	0.6	205
375	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 2009, 114, 3448-3458.	0.6	292
376	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood, 2009, 114, 5315-5321.	0.6	53
377	BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 765-765.	0.6	0
378	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. Blood, 2009, 114, 673-673.	0.6	0

#	Article	IF	Citations
379	DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.. Blood, 2009, 114, 707-707.	0.6	0
380	BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.. Blood, 2009, 114, 91-91.	0.6	1
381	Promoter Hypermethylation in MLL-r Leukemia: Biology and Therapeutic Targeting.. Blood, 2009, 114, 3472-3472.	0.6	0
382	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis.. Blood, 2009, 114, 3465-3465.	0.6	2
383	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. Blood, 2009, 114, 619-619.	0.6	10
384	BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.. Blood, 2009, 114, 2167-2167.	0.6	2
385	Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer. Molecular Cell, 2008, 29, 384-391.	4.5	144
386	BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells, Molecules, and Diseases, 2008, 41, 95-99.	0.6	84
387	Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leukemia and Lymphoma, 2008, 49, 874-882.	0.6	41
388	Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. Cancer Research, 2008, 68, 3361-3369.	0.4	30
389	BCL6-mediated Attenuation of DNA Damage Sensing Triggers Growth Arrest and Senescence through a p53-dependent Pathway in a Cell Context-dependent Manner. Journal of Biological Chemistry, 2008, 283, 22565-22572.	1.6	38
390	CtBP Is an Essential Corepressor for BCL6 Autoregulation. Molecular and Cellular Biology, 2008, 28, 2175-2186.	1.1	53
391	Kaiso Contributes to DNA Methylation-Dependent Silencing of Tumor Suppressor Genes in Colon Cancer Cell Lines. Cancer Research, 2008, 68, 7258-7263.	0.4	101
392	Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood, 2008, 112, 644-651.	0.6	40
393	B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Current Opinion in Hematology, 2008, 15, 381-390.	1.2	71
394	Meta-Analysis of Microarray Studies Reveals a Novel Hematopoietic Progenitor Cell Signature and Demonstrates Feasibility of Inter-Platform Data Integration. PLoS ONE, 2008, 3, e2965.	1.1	20
395	BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. Blood, 2008, 112, 295-295.	0.6	34
396	Epigenetic Determinants of Pathogenesis and Resistance to Proteosome Inhibition in Mantle Cell Lymphoma.. Blood, 2008, 112, 3373-3373.	0.6	8

#	Article	IF	Citations
397	Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML). Blood, 2008, 112, 756-756.	0.6	2
398	Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling. Blood, 2008, 112, 757-757.	0.6	3
399	An Integrative Genomic and Epigenomic Approach for the Study of Transcriptional Regulation. PLoS ONE, 2008, 3, e1882.	1.1	77
400	Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma. Blood, 2008, 112, 602-602.	0.6	0
401	Genome-Wide Epigenetics in Myeloid Leukemias.. Blood, 2008, 112, sci-35-sci-35.	0.6	0
402	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3207-3212.	3.3	130
403	CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Research, 2007, 35, 6798-6807.	6.5	74
404	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 2007, 110, 2067-2074.	0.6	117
405	Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nature Immunology, 2007, 8, 705-714.	7.0	231
406	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. Blood, 2007, 110, 345-345.	0.6	2
407	Kaiso-Deficient Mice Show Resistance to Intestinal Cancer. Molecular and Cellular Biology, 2006, 26, 199-208.	1.1	146
408	Comparative isoschizomer profiling of cytosine methylation: The HELP assay. Genome Research, 2006, 16, 1046-1055.	2.4	355
409	Specific peptides for the therapeutic targeting of oncogenes. Current Opinion in Genetics and Development, 2006, 16, 71-77.	1.5	28
410	A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 616-616.	0.6	0
411	Reprogramming Specific Gene Expression Pathways in B-Cell Lymphomas. Cell Cycle, 2005, 4, 241-243.	1.3	6
412	The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?. Journal of Clinical Oncology, 2005, 23, 3957-3970.	0.8	31
413	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature Medicine, 2004, 10, 1329-1335.	15.2	272
414	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood, 2004, 103, 1454-1463.	0.6	70

#	Article	IF	Citations
415	The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood, 2004, 103, 4650-4658.	0.6	42
416	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Practice and Research in Clinical Haematology, 2003, 16, 387-408.	0.7	44
417	Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain. Molecular Cell, 2003, 12, 1551-1564.	4.5	251
418	Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors. Molecular and Cellular Biology, 2002, 22, 1804-1818.	1.1	200
419	Histone deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 2002, 9, 322-332.	1.2	101
420	Translocations of the RARÎ± gene in acute promyelocytic leukemia. Oncogene, 2001, 20, 7186-7203.	2.6	206
421	The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. Molecular and Cellular Biology, 2000, 20, 2075-2086.	1.1	134
422	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. Molecular and Cellular Biology, 2000, 20, 6550-6567.	1.1	13
423	The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. Molecular and Cellular Biology, 1998, 18, 5533-5545.	1.1	164
424	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. Cancer Discovery, 0, , OF1-OF20.	7.7	2